Navigation Links
Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
Date:3/31/2009

Inc., a private pharmaceutical company. In 2004, Narachi retired as an officer and Vice President and General Manager of Amgen's Anemia Business. Throughout his 20 years at Amgen, Narachi held various positions including: Product Development Team Leader for NEUPOGEN(R); Director of Clinical Operations in Thousand Oaks, Calif., and Cambridge, U.K.; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. He is also a director of AMAG Pharmaceuticals, Inc.

Mr. Narachi received B.S. and M.A. degrees in Molecular Genetics from the University of California at Davis. He also received an M.B.A. from the Anderson Graduate School of Management at University of California, Los Angeles.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
4. Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City
5. Oxygen Biotherapeutics, Inc. Establishes Warfighter Division
6. Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. MRSA study suggests strategy shift needed to develop effective therapeutics
9. Cell Therapeutics, Inc. (CTI) President Craig Philips to Present at Invest Northwest
10. MPM Capital Leads Investment in Proteon Therapeutics
11. Cell Therapeutics Reschedules Special Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... McNeil & Company , a ... of coverage for its Emergency Services Insurance Program ... insurance and proactive risk management to the emergency services ... to providing our customers with unparalleled service and the ... We are excited to launch over 100 new enhancements ...
(Date:5/4/2015)... Orange, NJ (PRWEB) May 04, 2015 ... non-profit organization devoted exclusively to funding innovative lymphoma research ... of education programs, outreach initiatives and patient services – ... at the historic Mayfair Farms in West Orange, NJ ... raised nearly $500,000 for innovative research programs through LRF. ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 METTLER ... The Importance of Data Integrity in a GXP ... as guest presenter. This webinar will be presented ... GMT). , Data integrity is a critical component ... to regulatory agencies. However, in recent years an ...
(Date:5/4/2015)... WA (PRWEB) May 04, 2015 EyeCRO ... a collaboration to facilitate development of NM108, a first-in-class ... that lead to blindness, including Diabetic Retinopathy. The ... platform developed by EyeCRO, which can deliver drugs to ... topical eyedrop. , Under the terms of the ...
(Date:5/4/2015)... Greensboro, NC (PRWEB) May 04, 2015 ... excited to offer this unique program to other leadership ... create valuable ties between CCL and successful practitioners, expanding ... organizations around the globe,” said John R. Ryan, CCL ... consultancy joins the CCL Partner Network , it ...
Breaking Medicine News(10 mins):Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2
... Amsterdam, The Netherlands: Only 35% of anaesthesiologists are carrying ... make a significant impact on how well patients recover ... (Sunday 12 June) at the European Anaesthesiology Congress in ... and US anaesthesiologists found that although more than 95% ...
... bleeding was higher in the most commonly implanted heart device ... Henry Ford Hospital in Detroit. The HeartMate II, a ... connected to the patient,s heart that takes over the pumping ... were more instances of bleeding in the skull and gastrointestinal ...
... -- Baseline concussion tests for athletes may do more harm ... concussion testing provides a baseline score of an athlete,s cognitive ... Athletes who suffer a concussion retake the test, and if ... typically banned from play until their score improves. But ...
... By Maureen Salamon HealthDay Reporter , FRIDAY, June ... be tied to better sex? That,s the finding ... adults against their reports of satisfaction in the bedroom. ... studied data from more than 3,200 men and women ages ...
... , FRIDAY, June 10 (HealthDay News) -- Urban development ... says. The study, led by researchers at ... that the sprawl of strip malls and other paved ... air quality during the summer months. In conducting ...
... and Afghanistan veterans who visited a VA integrated care ... health and social work evaluations than veterans who visited ... study led by a San Francisco VA Medical Center ... veterans, younger veterans, veterans with mental health diagnoses, and ...
Cached Medicine News:Health News:Important monitoring of heart performance is omitted in two-thirds of high-risk surgical operations 2Health News:Important monitoring of heart performance is omitted in two-thirds of high-risk surgical operations 3Health News:Internal bleeding higher with popular heart device than earlier model 2Health News:Validity of Baseline Concussion Tests Questioned 2Health News:Self-Confidence, Empathy May Make for Better Sex 2Health News:Self-Confidence, Empathy May Make for Better Sex 3Health News:City Pavement Affects Weather, Boosting Smog: Study 2Health News:'1-stop' clinic ups mental health, social work visits for veterans 2Health News:'1-stop' clinic ups mental health, social work visits for veterans 3
(Date:5/4/2015)... RadiologyAuction will have their first auction starting May ... at the end of the auction on May 27 ... Fuji Cr,s, Agfa and Sony, printers and GE portable ... imaging equipment will be available at later auctions each ... of buying and selling imaging equipment, the brokers at ...
(Date:5/4/2015)... 2015  Oncobiologics, Inc., a biotherapeutics company focused ... has completed the construction of its GMP commercial ... Cranbury, New Jersey . ... designed to utilize multiple technologies that enable rapid ... the use of the latest single-use technologies, the ...
(Date:5/4/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... the agreement, Isis is eligible to receive up to ... million up-front payment and a $55 million payment upon ... in patients with compromised kidney function. Isis is also ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... capability to quickly deliver up to 250 ... for powerful single-pulse ablation. This type of ... coldest and cleanest CO2 surgical laser available ... with the independent adjustment of pulse energy ...
... technology has allowed for perfecting mini-invasive endoscopic ... various pathologies with a considerable social impact. ... reducing the post-operatory times and represents a ... in all hospital structures.,DEKAs family of Nd:YAG ...
Medicine Products: